Showing results (171-180 of 277) with videos related to
Sort By:
Pageof 28
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Immune-mediated conditionsJeffrey D Cizenski, Pablo Michel, Ian T Watson, et al.Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.Dermatology and Therapy|May 19, 2022
Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)A David Burden, Ulrich Mrowietz, Anne M Skalicky, et al.Journal of the American Academy of Dermatology|August 20, 2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis CouncilBruce Strober, Caitriona Ryan, Peter van de Kerkhof, et al.American Journal of Clinical Dermatology|January 31, 2018
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or PsoriasisCaitriona Ryan, Jeffrey M Sobell, Craig L Leonardi, et al.Dermatologic Clinics|January 31, 2012
Quality-of-life instruments: evaluation of the impact of psoriasis on patientsMisha M Heller, Jillian W Wong, Tien V Nguyen, et al.Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.Journal of Drugs in Dermatology : JDD|February 5, 2013
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trialAlan Menter, Linda Stein Gold, Michael Bukhalo, et al.Expert Opinion on Biological Therapy|December 15, 2020
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO studyAlan Menter, Petr Arenberger, Sigrid Balser, et al.Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.Pageof 28